News
(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Garmezy discussing a phase 1 trial of mevrometostat (PF-06821497), a potent and ...
ASCO 2025 CA209-8TY trial, phase 2 trial of nivolumab and ipilimumab, stereotactic body radiation therapy, metastatic castration-resistant prostate cancer (mCRPC), androgen receptor pathway inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback